Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
Matthew O. Burrell
Research Funding - DiaTech Oncology
Michael Stany
Research Funding - DiaTech Oncology
James Rutledge
Other Remuneration - DiaTech Oncology
Emery Manuel Salom
Research Funding - DiaTech Oncology
Manuel Penalver
Research Funding - DiaTech Oncology
Allan Hallquist
Employment or Leadership Position - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Other Remuneration - DiaTech Oncology
Cary A. Presant
Employment or Leadership Position - DiaTech Oncology
Consultant or Advisory Role - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Research Funding - DiaTech Oncology